Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab - guidance (TA472)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
30 August 2017

Abstract

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma that did not respond or progressed after treatment with rituximab.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: More evidence on obinutuzumab is being collected, until December 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Commercial arrangement

There is a managed access agreement, which includes a simple discount patient access scheme for obinutuzumab. Contact Welwyn.rx_bdop@roche.com for details.